[1] Lee JC, Yamauchi H, Hopper J. The association of cancer and the nephrotic syndrome[J]. Ann Intern Med, 1966, 64(1):41-51. DOI: 10.7326/0003-4819-64-1-41.
[2] Bouatou Y, Koessler T, Oniszczuk J, et al. Nephrotic syndrome in small cell lung cancer and induction of c-mip in podocytes[J]. Am J Kidney Dis, 2017, 69(3):477-480. DOI: 10.1053/j.ajkd.2016.09.026.
[3] Jansen AME, Sriram JD, Pluim D, et al. Therapeutic exposure and successful response to pembrolizumab in a patient with non-small-cell lung cancer despite significant renal loss due to paraneoplastic nephrotic syndrome[J]. Clin Lung Cancer, 2021, 22(2):e220-e223. DOI: 10.1016/j.cllc.2020.09.021.
[4] Caruana RJ, Griffin JW. Nephrotic syndrome in a patient with ulcerative colitis and colonic carcinoma[J]. Am J Gastroenterol, 1980, 74(6):525-528.
[5] Audard V, Larousserie F, Grimbert P, et al. Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature[J]. Kidney Int, 2006, 69(12):2251-2260. DOI: 10.1038/sj.ki.5000341.
[6] Werner TL, Agarwal N, Carney HM, et al. Management of cancer-associated thrombotic microangiopathy: what is the right approach? [J]. Am J Hematol, 2007, 82(4):295-298. DOI: 10.1002/ajh.20783.
[7] Rojas-Marcos I, Rousseau A, Keime-Guibert F, et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer[J]. Medicine (Baltimore), 2003, 82(3):216-223. DOI: 10.1097/01.md.0000076004.64510.ce.
[8] Shildkrot Y, Sobrin L, Gragoudas ES. Cancer-associated retinopathy: update on pathogenesis and therapy[J]. Semin Ophthalmol, 2011, 26(4-5):321-328. DOI: 10.3109/08820538.2011.588657.
[9] Sayman C, Tireli H, Gürleyik GM. Cancer-associated retinopathy in patients with newly diagnosed breast tumor[J]. Noro Psikiyatr Ars, 2021, 58(4):278-282. DOI: 10.29399/npa.25097.
[10] Kim JH, Kim SC. Paraneoplastic pemphigus: paraneoplastic autoimmune disease of the skin and mucosa[J]. Front Immunol, 2019, 10:1259. DOI: 10.3389/fimmu.2019.01259.
[11] Manger B, Schett G. Paraneoplastic syndromes in rheumatology[J]. Nat Rev Rheumatol, 2014, 10(11):662-670. DOI: 10.1038/nrrheum.2014.138.
[12] Onyema MC, Drakou EE, Dimitriadis GK. Endocrine abnormality in paraneoplastic syndrome[J]. Best Pract Res Clin Endocrinol Metab, 2022, 36(3):101621. DOI: 10.1016/j.beem.2022.101621.
[13] Kim YT, Rha SY, Shim CY, et al. A case of paraneoplastic nephrotic syndrome in a patient with ovarian carcinoma[J]. Yonsei Med J, 2003, 44(3):539-543. DOI: 10.3349/ymj.2003.44.3.539.
[14] Viau M, Renaud MC, Grégoire J, et al. Paraneoplastic syndromes associated with gynecological cancers: a systematic review[J]. Gynecol Oncol, 2017, 146(3):661-671. DOI: 10.1016/j.ygyno.2017.06.025.
[15] Kilis-Pstrusinska K, Szajerka U, Zwolinska D. Unspecific increase of tumor markers in a girl with nephrotic syndrome and ovarian teratoma[J]. Ren Fail, 2013, 35(5):654-656. DOI: 10.3109/0886022X.2013.780614.
[16] Mallouk A, Pham PT, Pham PC. Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies[J]. Clin Exp Nephrol, 2006, 10(4):284-289. DOI: 10.1007/s10157-006-0437-4.
[17] Taylor EC, Irshaid L, Mathur M. Multimodality imaging approach to ovarian neoplasms with pathologic correlation[J]. Radiographics, 2021, 41(1):289-315. DOI: 10.1148/rg.2021200086.
[18] Boger-Megiddo I, Weiss NS. Histologic subtypes and laterality of primary epithelial ovarian tumors[J]. Gynecol Oncol, 2005, 97(1):80-83. DOI: 10.1016/j.ygyno.2004. 11.054.
[19] Okada S, Ohaki Y, Inoue K, et al. Calcifications in mucinous and serous cystic ovarian tumors[J]. J Nippon Med Sch, 2005, 72(1):29-33. DOI: 10.1272/jnms.72.29.
[20] 李宁,吴令英.中国临床肿瘤学会«卵巢癌诊疗指南(2021年版)»更新要点[J].中国实用妇科与产科杂志,2021,37(7):720-723. DOI:10.19538/j.fk2021070109.
[21] Lefaucheur C, Stengel B, Nochy D, et al. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association[J]. Kiney Int, 2006, 70(8):1510-1517. DOI: 10.1038/sj.ki.5001790.
[22] Hung CC, Zhen YY, Niu SW, et al. Lung cancer cell-derived secretome mediates paraneoplastic inflammation and fibrosis in kidney in mice[J]. Cancers (Basel), 2020, 12(12):3561. DOI: 10.3390/cancers12123561.
|